Insider · CIK 0001718020
Machelle Sanders
Files at BCRX (BIOCRYST PHARMACEUTICALS INC), FTRE (Fortrea Holdings Inc.). First filing Jun 17, 2024, latest Aug 5, 2026.
In brief
Machelle Sanders files SEC Form 4 as director at BCRX (BIOCRYST PHARMACEUTICALS INC), and also at FTRE (Fortrea Holdings Inc.). Since Jun 17, 2024, Machelle Sanders has reported 0 open-market buys worth $0 and 3 open-market sells worth $271k, the latest filed on Aug 5, 2026.
A track record needs three past buys with six months of prices behind them; Machelle Sanders has 0, so none is measured yet.
The newest scored trade: sold $175k of FTRE on Aug 3, 2026, filed Aug 5, 2026, scored 39 (weak). In the last 12 months: 0 buys worth $0 and 2 sells worth $243k.
Where the trades landed
Last year at the 2 companies this insider has traded most, with each buy and sell on the bar it happened.
BCRX: BIOCRYST PHARMACEUTICALS INC
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
FTRE: Fortrea Holdings Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 39Weak | Fortrea Holdings Inc. | $175k 9,700 shares | -21% | +196% from low-9% from high | |
| 8Weak | BIOCRYST PHARMACEUTICALS INC | $69k 9,600 shares | -24% | +8% from low-38% from high | |
| 40Moderate | BIOCRYST PHARMACEUTICALS INC | $28k 4,689 shares | -14% | +51% from low-21% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Aug 3, 2026 | FTRE Fortrea Holdings Inc. | 9,700 0.01% of outstanding | $175k | Aug 3, 2026 | none |
| Nov 13, 2025 | BCRX BIOCRYST PHARMACEUTICALS INC | 9,600 0.00% of outstanding | $69k | Nov 13, 2025 | none |
| Jun 17, 2024 | BCRX BIOCRYST PHARMACEUTICALS INC | 4,689 0.00% of outstanding | $28k | Jun 17, 2024 | none |
Transactions
Every row this insider has filed, 16 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 3, 2026 | FTRE Fortrea Holdings Inc. | SOpen-market sale Common Stock | -9,700 | $18.01 | $175k | 36,399 | Aug 5, 2026 |
| Jun 11, 2026 | BCRX BIOCRYST PHARMACEUTICALS INC | AGrant or award Common Stock | +15,294 | $0.00 | $0 | 45,936 | Jun 15, 2026 |
| Jun 11, 2026 | BCRX BIOCRYST PHARMACEUTICALS INC | AGrant or award Automatic Stock Option Grantderivative | +33,540 | $0.00 | $0 | 33,540 | Jun 15, 2026 |
| Jun 10, 2026 | FTRE Fortrea Holdings Inc. | MOption exercise Common Stock | +38,817 | $0.00 | $0 | 46,099 | Jun 12, 2026 |
| Jun 10, 2026 | FTRE Fortrea Holdings Inc. | MOption exercise Restricted Stock Unitderivative | -38,817 | $0.00 | $0 | 0 | Jun 12, 2026 |
| Jun 10, 2026 | FTRE Fortrea Holdings Inc. | AGrant or award Restricted Stock Unitderivative | +12,852 | $0.00 | $0 | 12,852 | Jun 12, 2026 |
| Nov 13, 2025 | BCRX BIOCRYST PHARMACEUTICALS INC | SOpen-market sale Common Stock10b5-1 | -9,600 | $7.14 | $69k | 30,642 | Nov 17, 2025 |
| Jun 12, 2025 | BCRX BIOCRYST PHARMACEUTICALS INC | AGrant or award Common Stock | +12,500 | $0.00 | $0 | 40,242 | Jun 16, 2025 |
| Jun 12, 2025 | BCRX BIOCRYST PHARMACEUTICALS INC | AGrant or award Automatic Stock Option Grantderivative | +27,181 | $0.00 | $0 | 27,181 | Jun 16, 2025 |
| Jun 10, 2025 | FTRE Fortrea Holdings Inc. | AGrant or award Restricted Stock Unitderivative | +38,817 | $0.00 | $0 | 38,817 | Jun 12, 2025 |
| May 14, 2025 | FTRE Fortrea Holdings Inc. | MOption exercise Common Stock | +7,282 | $0.00 | $0 | 7,282 | May 16, 2025 |
| May 14, 2025 | FTRE Fortrea Holdings Inc. | MOption exercise Restricted Stock Unitderivative | -7,282 | $0.00 | $0 | 0 | May 16, 2025 |
| Jun 17, 2024 | BCRX BIOCRYST PHARMACEUTICALS INC | SOpen-market sale Common Stock | -4,689 | $6.00 | $28k | 27,742 | Jun 17, 2024 |
| Jun 12, 2024 | BCRX BIOCRYST PHARMACEUTICALS INC | AGrant or award Common Stock | +6,820 | $0.00 | $0 | 32,431 | Jun 14, 2024 |
| Jun 12, 2024 | BCRX BIOCRYST PHARMACEUTICALS INC | AGrant or award Automatic Stock Option Grantderivative | +49,933 | $0.00 | $0 | 49,933 | Jun 14, 2024 |
| May 14, 2024 | FTRE Fortrea Holdings Inc. | AGrant or award Restricted Stock Unitderivative | +7,282 | $0.00 | $0 | 7,282 | May 16, 2024 |
Questions about Machelle Sanders
Answered from the filings on this page, as of the latest one.
Is Machelle Sanders buying or selling?
In the last 12 months Machelle Sanders reported 0 open-market buys worth $0 and 2 open-market sells worth $243k on SEC Form 4; the latest was sold $175k of FTRE on Aug 3, 2026. Grants, option exercises and tax withholding are not counted.
How did Machelle Sanders's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Machelle Sanders has 0.
Where does Machelle Sanders file Form 4?
Machelle Sanders has filed Form 4 at BCRX (BIOCRYST PHARMACEUTICALS INC); FTRE (Fortrea Holdings Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.